GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Olympus Corp (FRA:OLY1) » Definitions » COGS-to-Revenue

Olympus (FRA:OLY1) COGS-to-Revenue : 0.33 (As of Dec. 2024)


View and export this data going back to . Start your Free Trial

What is Olympus COGS-to-Revenue?

Olympus's Cost of Goods Sold for the three months ended in Dec. 2024 was €517 Mil. Its Revenue for the three months ended in Dec. 2024 was €1,560 Mil.

Olympus's COGS to Revenue for the three months ended in Dec. 2024 was 0.33.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. Olympus's Gross Margin % for the three months ended in Dec. 2024 was 66.87%.


Olympus COGS-to-Revenue Historical Data

The historical data trend for Olympus's COGS-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Olympus COGS-to-Revenue Chart

Olympus Annual Data
Trend Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25
COGS-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.37 0.32 0.32 0.33 0.31

Olympus Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
COGS-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.33 0.33 0.30 0.33 -

Olympus COGS-to-Revenue Calculation

Olympus's COGS to Revenue for the fiscal year that ended in Mar. 2025 is calculated as

COGS to Revenue=Cost of Goods Sold / Revenue
=1946.31 / 6189.098
=0.31

Olympus's COGS to Revenue for the quarter that ended in Dec. 2024 is calculated as

COGS to Revenue=Cost of Goods Sold / Revenue
=516.651 / 1559.597
=0.33

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Olympus  (FRA:OLY1) COGS-to-Revenue Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

Olympus's Gross Margin % for the three months ended in Dec. 2024 is calculated as:

Gross Margin %=1 - COGS to Revenue
=1 - Cost of Goods Sold / Revenue
=1 - 516.651 / 1559.597
=66.87 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.


Olympus COGS-to-Revenue Related Terms

Thank you for viewing the detailed overview of Olympus's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Olympus Business Description

Traded in Other Exchanges
Address
Shinjuku Monolith, 2-3-1 Nishi-Shinjuku, Shinjuku-ku, Tokyo, JPN, 163-0914
Olympus is a medical device maker with a leading position in the endoscope market and a diversified global revenue stream. Originally founded in 1919 in Japan as a microscope and camera maker, Olympus has gradually pivoted into endoscopic and therapeutic solutions. As of March 2024, more than 60% of its revenue comes from endoscopic solutions. In addition, North America is the biggest revenue contributor by region, accounting for 38% of its total revenue.

Olympus Headlines

No Headlines